Belgian body praises regulatory overhaul

Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.

More from Drug Pricing

More from Policy & Regulation